Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 818

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 818
---
 (3) | Transaction costs primarily relate to bank fees and professional fees associated with legal counsel. |

The purchase price for the Merger was allocated to the assets acquired and liabilities on a relative fair value basis as follows

| Assets:                                        |     | (in thousands) |        |   |
|:-----------------------------------------------|:----|:---------------|-------:|:--|
| Cash and cash equivalents                      |     | $              |  9,226 |   |
| Accounts receivable                            |     |                |    100 |   |
| Prepaid expenses and other current assets      |     |                |    176 |   |
| Property and equipment, net                    |     |                |     65 |   |
| Restricted cash                                |     |                |     50 |   |
| In-process research and development            |     |                | 18,860 |   |
| Liabilities:                                   |     |                |        |   |
| Accounts payable                               |     |                |   (296 | ) |
| Accrued expenses and other current liabilities |     |                | (1,547 | ) |
| Deferred revenue                               |     |                |   (442 | ) |
| Total purchase price                           |     | $              | 26,192 |   |

F-94

KINETA, INC. Notes to Consolidated Financial Statements The acquired in-processresearch and development assets relate to three product candidates. Due to the early stages of development of these assets at the date of acquisition, it was not probable that there was future economic benefit from the assets and there was no alternative future use associated with the assets. Accordingly, the acquired IPR&D was expensed in the consolidated statement of operations for the year ended December 31, 2022. 4. Fair Value Measurements The carrying amounts of the Company’s financial instruments, including cash, restricted cash, and accounts payable, approximate fair value due to the short-term nature of those instruments. Rights from Private Placement In connection and concurrently with the execution of the Merger Agreement, on June 5, 2022, the Company entered into a financing agreement, as amended on October 24, 2022, December 5, 2022 and March 29, 2023 May 1, 2023, July 21, 2023 and October 13, 2023 (such financing agreement, as amended, the “Securities Purchase Agreement”), to sell shares of the Company’s common